ENDOLOGIX INC's ticker is and the CUSIP is 29266SAA4. A total of 17 filers reported holding ENDOLOGIX INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $58,000 | -1.7% | 58,237 | -1.7% | 0.00% | – |
| Q2 2018 | $59,000 | +1.7% | 59,262 | +2.4% | 0.00% | – |
| Q1 2018 | $58,000 | +31.8% | 57,876 | +33.0% | 0.00% | – |
| Q4 2017 | $44,000 | 0.0% | 43,513 | 0.0% | 0.00% | – |
| Q3 2017 | $44,000 | 0.0% | 43,513 | 0.0% | 0.00% | – |
| Q2 2017 | $44,000 | 0.0% | 43,513 | -0.2% | 0.00% | – |
| Q1 2017 | $44,000 | +388.9% | 43,600 | +336.0% | 0.00% | – |
| Q4 2016 | $9,000 | -10.0% | 10,000 | 0.0% | 0.00% | – |
| Q3 2016 | $10,000 | +11.1% | 10,000 | 0.0% | 0.00% | – |
| Q2 2016 | $9,000 | +28.6% | 10,000 | 0.0% | 0.00% | – |
| Q1 2016 | $7,000 | -22.2% | 10,000 | 0.0% | 0.00% | – |
| Q3 2015 | $9,000 | -55.0% | 10,000 | -50.0% | 0.00% | – |
| Q2 2015 | $20,000 | +100.0% | 20,000 | +100.0% | 0.00% | – |
| Q1 2015 | $10,000 | 0.0% | 10,000 | 0.0% | 0.00% | – |
| Q4 2014 | $10,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 51,117,000 | $46,140,000 | 1.90% |
| PFM Health Sciences, LP | 6,445,000 | $5,809,000 | 0.16% |
| Partner Investment Management, L.P. | 84,000 | $76,000 | 0.10% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 5,562,000 | $5,013,000 | 0.09% |
| OAKTREE CAPITAL MANAGEMENT LP | 6,000,000 | $5,423,000 | 0.08% |
| PALISADE CAPITAL MANAGEMENT, LP | 1,095,000 | $1,004,000 | 0.04% |
| ACUTA CAPITAL PARTNERS, LLC | 96,000 | $86,000 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,500,000 | $1,352,000,000 | 0.03% |
| AMUNDI ASSET MANAGEMENT US, INC. | 7,305,000 | $6,557,000 | 0.02% |
| Citadel Advisors | 6,230,000 | $5,624,000 | 0.01% |